Compare TRAK & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRAK | TTRX |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.2M | 281.2M |
| IPO Year | 1996 | N/A |
| Metric | TRAK | TTRX |
|---|---|---|
| Price | $8.51 | $8.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 53.6K | ★ 128.5K |
| Earning Date | 05-14-2026 | 05-31-2026 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | ★ 20.69 | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $21,007,076.00 | N/A |
| Revenue This Year | $6.61 | N/A |
| Revenue Next Year | $10.04 | N/A |
| P/E Ratio | $29.11 | ★ N/A |
| Revenue Growth | ★ 4.84 | N/A |
| 52 Week Low | $6.94 | $2.57 |
| 52 Week High | $18.47 | $11.69 |
| Indicator | TRAK | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.66 | 47.75 |
| Support Level | $8.11 | $4.40 |
| Resistance Level | $9.09 | $11.69 |
| Average True Range (ATR) | 0.28 | 1.04 |
| MACD | -0.06 | -0.22 |
| Stochastic Oscillator | 51.81 | 4.52 |
ReposiTrak Inc is a software-as-a-service (SaaS) company based in Murray, Utah, specializing in supply chain management solutions for retailers, suppliers, and wholesalers, prominently in the food industry. The company offers three main product suites: ReposiTrak Compliance Management, ReposiTrak Traceability Network, and ReposiTrak Supply Chain Solutions. These platforms help customers comply with food safety regulations, manage supplier compliance documentation, trace products through the supply chain, and optimize supply chain operations. The company derives revenue from five sources: (i) subscription fees, (ii) transaction-based fees, (iii) professional services fees, (iv) license fees, and (v) hosting and maintenance fees.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.